Targeting HDACs: A Promising Therapy for Alzheimer's Disease
Author Information
Author(s): Xu Ke, Dai Xue-Ling, Huang Han-Chang, Jiang Zhao-Feng
Primary Institution: Capital Normal University, Beijing, China
Hypothesis
The physiological roles of HDACs may provide a new perspective to understand the mechanism of Alzheimer's disease and to develop selective HDAC inhibitors.
Conclusion
HDAC inhibitors may ameliorate cognitive deficits and memory impairment in Alzheimer's disease animal models.
Supporting Evidence
- HDAC inhibitors have been reported to improve memory and cognition in mouse models of Alzheimer's disease.
- Valproic acid significantly reduces Aβ plaque in AD transgenic mice.
- Nicotinamide restores cognitive deficits in 3xTg-AD mice.
- Phenylbutyrate ameliorates cognitive deficits in Tg2576 mice.
Takeaway
This study suggests that certain drugs can help improve memory in Alzheimer's disease by affecting how genes are turned on and off in the brain.
Methodology
The paper reviews recent research on HDAC proteins and their inhibitors in the context of Alzheimer's disease treatment.
Limitations
The exact role of specific HDAC subtypes in Alzheimer's disease and the effectiveness of selective HDAC inhibitors remain unclear.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website